Searchable abstracts of presentations at key conferences on calcified tissues

ba0003pp69 | Bone development/growth and fracture repair | ECTS2014

Enhancement of fracture repair by upregulation of the innate immune response

Santo Ana Isabel Espirito , Chan James K , Glass Graeme E , Ersek Adel , Freidin Andrew , Williams Garry A , Gowers Kate , Jeffery Rosemary , Otto William R , Poulsom Richard , Feldmann Marc , Rankin Sara M , Horwood Nicole J , Nanchahal Jagdeep

Osteoporotic fractures are very common and represent an enormous unmet medical need. Our group has previously reported that addition of rTNF to the fracture site promotes fracture healing in C57/BL6 mice (Glass et al. PNAS 2011). Using a murine fracture model of endochondral healing, we observed that local addition of rTNF only accelerates fracture repair if administered within the first 24 h following injury. The optimal therapeutic dose is 1 ng. TNF is firs...

ba0005oc3.6 | Clinical trials, FGF-23 and focal osteoporosis | ECTS2016

Focal osteoporosis associated with hip fracture involves both trabecular and cortical bone; a 3D cortical bone mapping study of cases and controls using clinical CT

Poole Ken , Skingle Linda , Gee Andrew , Turmezei Thomas , Johannesdottir Fjola , Blesic Karen , Rose Collette , Vindlacheruvu Madhavi , Donnell Simon , Vaculik Jan , Dungl Pavel , Horak Martin , Stepan Jan , Reeve Jonathan , Treece Graham

Focal cortical thinning and loss of trabecular structure in the proximal femur is associated with hip fracture. We analysed clinical computed tomography (CT) scans in cases and controls to explore their contributions to hip fracture in women.We used cortical bone mapping (CBM) and statistical parametric mapping (SPM) after combining women with hip fracture from FEMCO and Prague Hip Joint in Trauma studies (n=138, 52 Trochanteric and 86 Femoral N...

ba0005p128 | Cancer and bone: basic, translational and clinical | ECTS2016

The pharmacological profile of a novel highly potent bisphosphonate, OX14 (1-fluoro-2-(imidazo-[1,2 alpha]pyridin-3-yl)ethyl-bisphosphonate), with reduced bone affinity, which is as effective as zoledronate in the treatment of myeloma bone disease in JJN3-NOD/SCID-γ mice

Lawson Michelle , Chantry Andrew , Paton-Hough Julia , Evans Holly , Lath Darren , Tsoumpra Maria , Lundy Mark , Dobson Roy , Quijano Michael , Kwaasi Aaron , Dunford James , Duan Xuchen , Triffit James , Mazur Adam , Jeans Gwyn , Russell Graham , Ebetino Hal

Bisphosphonates are used in the treatment of a variety of diseases with skeletal complications. With the development of more potent compounds, there is the potential for further improvement. One concept is to use compounds with a reduced affinity for bone, reducing their long-term retention and possible adverse events, as well as potentially enhancing their non-skeletal benefits. We hypothesise that a highly potent bisphosphonate with low bone affinity, known as OX14, will be ...

ba0001oc4.4 | Osteoblasts and osteocytes | ECTS2013

Glucocorticoid exposure reduces expression of sclerostin in bone marrow stromal cells

Thiele Sylvia , Rauch Alexander , Tuckermann Jan P , Hofbauer Lorenz C , Rauner Martina

Glucocorticoids (GC) are effective drugs in the treatment of inflammatory diseases, including various forms of arthritis. However, their use is limited by negative effects on bone mass and strength, resulting in increased osteoporotic fractures. Conditional knockout mice demonstrated that the GR in osteoblasts is essential for GC-dependent bone loss. Recent studies show that GC profoundly inhibit Wnt signaling by stimulating the expression of Wnt antagonists such as dickkopf-1...

ba0001pp145 | Cancer and bone: basic, translational and clinical | ECTS2013

Synergistic anti-tumour effects on human breast cancer cells by mevalonate pathway inhibitors atorvastatin and zoledronic acid

Gobel Andy , Thiele Stefanie , Rauner Martina , Lorenz C Hofbauer , Tilman D Rachner

Introduction: Bone metastases represent a frequent complication of breast cancer and are characterized by increased tumour-driven activation of osteoclasts and subsequent bone loss. Aminobisphosphonates inhibit osteoclast function and are established therapies of skeletal metastases. Similar to statins, they block the mevalonate pathway and are thought to have direct anti-tumour effects. Here, we report on the anti-tumour potential of a sequential inhibition of the mevalonate ...

ba0001pp228 | Cell biology: osteoclasts and bone resorption | ECTS2013

Bisphosphonates differently affect jaw and long-bone marrow cells

Vermeer Jenny A F , Jansen Ineke D C , Renders Greetje A P , de Vries Teun J , Everts Vincent

Bisphosphonates (BPs) such as zoledronic acid (ZA) are widely used to treat bone diseases. The use of BPs can lead to osteonecrosis of the jaw (ONJ), but it is not clear why in particular the jaw bone is affected. Previously, it was shown that osteoclasts derived from different bone sites have different properties. We hypothesize that BPs have distinct effects on bone-site specific osteoclasts or precursors. To investigate this, female C57BL/6J mice were injected intraperitone...

ba0001pp280 | Genetics | ECTS2013

Association between dentinogenesis imperfecta and mutations in COLIA1 and COLIA2 genes

Andersson Kristofer , Dahllof Goran , Astrom Eva , Rubin C-J , Kindmark A , Lindahl Katarina , Ljunggren Osten , Malmgren Barbro

Introduction: Dentinogenesis imperfecta (DI) is a common dental aberration in patients with osteogenesis imperfecta (OI). Mutations that cause abnormal collagen chains will cause more serious types of OI and it has been claimed that DI should be a marker for qualitative defected collagen. It has also been supposed that normal development of teeth may be more dependent on normal α2(I) than normal α1(I) chains which are encoded by COLIA2 and COLIA1 ge...